A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Acquired Blepharoptosis
Спонсор: Santen
Налично на:
БГ
Обобщение
Trial status: Authorised
PRO: PGIC on Day 14
Change from baseline in MRD1 on Day 14
Описание
PRO: PGIC on Day 14
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 291 participants
БГ
EN